40 Years of RAS-A Historic Overview - PubMed
- ️Fri Jan 01 2021
Review
40 Years of RAS-A Historic Overview
Alberto Fernández-Medarde et al. Genes (Basel). 2021.
Abstract
It has been over forty years since the isolation of the first human oncogene (HRAS), a crucial milestone in cancer research made possible through the combined efforts of a few selected research groups at the beginning of the 1980s. Those initial discoveries led to a quantitative leap in our understanding of cancer biology and set up the onset of the field of molecular oncology. The following four decades of RAS research have produced a huge pool of new knowledge about the RAS family of small GTPases, including how they regulate signaling pathways controlling many cellular physiological processes, or how oncogenic mutations trigger pathological conditions, including developmental syndromes or many cancer types. However, despite the extensive body of available basic knowledge, specific effective treatments for RAS-driven cancers are still lacking. Hopefully, recent advances involving the discovery of novel pockets on the RAS surface as well as highly specific small-molecule inhibitors able to block its interaction with effectors and/or activators may lead to the development of new, effective treatments for cancer. This review intends to provide a quick, summarized historical overview of the main milestones in RAS research spanning from the initial discovery of the viral RAS oncogenes in rodent tumors to the latest attempts at targeting RAS oncogenes in various human cancers.
Keywords: GTPases; RAS; cancer; history; milestones.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Milestones in RAS research. Summarized timeline of some key discoveries in RAS research over the last 40 years. We apologize for many key discoveries that could not be included here due to lack of space. The individual boxes point to the year of publication of some selected research advances that significantly contributed to the path leading to our current understanding of RAS structure, function and biology.

The RAS superfamily. Protein phylogenetic tree, including 150 human small GTPases corresponding to distinct, protein-coding gene loci (proteins annotated in the UniProt database). The HRAS sequence was used as the root for tree construction based on the distance matrix derived from the multiple alignment of the 150 amino-acid sequences using the neighbor joining method [33]. The tree includes 36 members of the RAS family (blue), 20 members of the RHO/RAC family (purple), 26 of the ARF family (brown), 60 of the RAB family (green) and 1 of the RAN family (red). Seven proteins that are frequently unclassified are identified here (pointed by arrows in the figure) as RHO-like (2), ARF-like (2) and RAB-like (3).
Similar articles
-
A perspective on the early days of RAS research.
Weiss RA. Weiss RA. Cancer Metastasis Rev. 2020 Dec;39(4):1023-1028. doi: 10.1007/s10555-020-09919-1. Epub 2020 Jul 29. Cancer Metastasis Rev. 2020. PMID: 32728828 Free PMC article. Review.
-
Oncogenic RAS: From Its Activation to Its Direct Targeting.
Zaravinos A. Zaravinos A. Crit Rev Oncog. 2017;22(3-4):283-301. doi: 10.1615/CritRevOncog.2017024695. Crit Rev Oncog. 2017. PMID: 29604905 Review.
-
A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting.
Shu L, Wang D, Saba NF, Chen ZG. Shu L, et al. Mol Cancer Ther. 2020 Apr;19(4):999-1007. doi: 10.1158/1535-7163.MCT-19-0660. Mol Cancer Ther. 2020. PMID: 32241873 Review.
-
The RAS-Effector Interaction as a Drug Target.
Keeton AB, Salter EA, Piazza GA. Keeton AB, et al. Cancer Res. 2017 Jan 15;77(2):221-226. doi: 10.1158/0008-5472.CAN-16-0938. Epub 2017 Jan 6. Cancer Res. 2017. PMID: 28062402 Free PMC article. Review.
-
RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA, Haris M, Dermime S, Uddin S. Khan AQ, et al. Semin Cancer Biol. 2019 Feb;54:1-13. doi: 10.1016/j.semcancer.2018.03.001. Epub 2018 Mar 7. Semin Cancer Biol. 2019. PMID: 29524560 Review.
Cited by
-
Endomembrane-Based Signaling by GPCRs and G-Proteins.
Liccardo F, Luini A, Di Martino R. Liccardo F, et al. Cells. 2022 Feb 3;11(3):528. doi: 10.3390/cells11030528. Cells. 2022. PMID: 35159337 Free PMC article. Review.
-
Post-embryonic endogenous expression and localization of LET-60/Ras in C. elegans.
Jayadev R, Chi Q, Sherwood DR. Jayadev R, et al. MicroPubl Biol. 2023 Aug 25;2023:10.17912/micropub.biology.000931. doi: 10.17912/micropub.biology.000931. eCollection 2023. MicroPubl Biol. 2023. PMID: 37692087 Free PMC article.
-
An ultra-sensitive method to detect mutations in human RAS templates.
Li S, Counter CM. Li S, et al. Small GTPases. 2022 Jan;13(1):287-295. doi: 10.1080/21541248.2022.2083895. Small GTPases. 2022. PMID: 35658790 Free PMC article.
-
Gupta K, Jones JC, Farias VA, Mackeyev Y, Singh PK, Quiñones-Hinojosa A, Krishnan S. Gupta K, et al. Front Oncol. 2022 May 18;12:840241. doi: 10.3389/fonc.2022.840241. eCollection 2022. Front Oncol. 2022. PMID: 35664781 Free PMC article.
-
Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways.
Cháirez-Ramírez MH, de la Cruz-López KG, García-Carrancá A. Cháirez-Ramírez MH, et al. Front Pharmacol. 2021 Oct 20;12:710304. doi: 10.3389/fphar.2021.710304. eCollection 2021. Front Pharmacol. 2021. PMID: 34744708 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous